BioAtla shares slipped after an early jump as investors evaluated a $40-million single-asset SPV to fund a Phase 3 trial of Oz-V. The structure lets BioAtla avoid a large equity raise while retaining 65% ownership of the asset across solid-tumor uses. Phase 3 enrolment is slated to begin in early 2026.